Biotechnology company NKMax America stated on Tuesday that it has dosed its first patient with plaque psoriasis under its SNK01-MX03 phase I clinical trial of SNK at Angeles Hospital,Tijuana, Mexico.
The company said SNK is an ex vivo expanded autologous natural killer cell therapeutic manufactured by harvesting a small number of a patient's immune cells. After harvesting, NK cells are separated from the blood, purified, activated and expanded in a cGMP facility. The activated NK cells (SNK) are reinfused in the patient to suppress the inflammatory response attributed to psoriasis.
This single centre, dose escalation SNK01-MX03 phase I clinical trial will evaluate SNK administered intravenously once a week for four weeks at three different dosing levels.
According to the company, it will enroll nine subjects in the trial to investigate the safety and tolerability of SNK in adults with mild to severe plaque psoriasis.
In conjunction, the SNK study for psoriasis is currently recruiting participants the state-of-the-art Angeles hospital in Tijuana, Mexico, concluded the company.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007